Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.
The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.
Chaudhry
V
V
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vchaudh@jhmi.edu
Cornblath
D R
DR
Griffin
J W
JW
O'Brien
R
R
Drachman
D B
DB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D009220:Myositis / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid